Clinical Trial

Diazoxide Suppression Test P&F Study

Study acronym: DzST
Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Reprioritization of research efforts
Summary
The goal of this study is to learn about how the hormone insulin controls blood sugar. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. People with obesity and high insulin levels will receive eight doses of diazoxide, a drug that suppresses the pancreas's production of insulin, and will have their fasting blood sugar and insulin levels checked daily while taking the drug.
Protocol Amendment History 5 changes
critical Trial terminated 2026-08-08
critical Trial terminated: Reprioritization of research efforts 2026-08-08
notable Enrollment reduced: 10 -> 1 participants 2026-08-08
notable Primary completion moved earlier: 2027-11 -> 2026-06-10 2026-08-08
minor Completion moved earlier: 2028-01 -> 2026-06-10 2026-08-08
Trial Details
NCT Number NCT06606327
Lead Sponsor Columbia University
Collaborators: University of Pisa
Conditions Insulin Resistance, Hyperinsulinemia, Obesity
Enrollment 1 participants
Start Date 2024-10-23
Primary Completion 2026-06-10 (estimated)
Study Completion 2026-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-07